154 related articles for article (PubMed ID: 27252739)
1. Comparison of the effects of eldecalcitol with either raloxifene or bisphosphonate on serum tartrate resistant acid phosphatase-5b, a bone resorption marker, in postmenopausal osteoporosis.
Takada J; Ikeda S; Kusanagi T; Mizuno S; Wada H; Iba K; Yoshizaki T; Yamashita T
Clin Cases Miner Bone Metab; 2016; 13(1):25-8. PubMed ID: 27252739
[TBL] [Abstract][Full Text] [Related]
2. Eldecalcitol, in Combination with Bisphosphonate, Is Effective for Treatment of Japanese Osteoporotic Patients.
Mukaiyama K; Uchiyama S; Nakamura Y; Ikegami S; Taguchi A; Kamimura M; Kato H
Tohoku J Exp Med; 2015 Dec; 237(4):339-43. PubMed ID: 26639092
[TBL] [Abstract][Full Text] [Related]
3. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment.
Iba K; Sonoda T; Takada J; Dohke T; Yamashita T
J Bone Miner Metab; 2017 Mar; 35(2):171-176. PubMed ID: 26832388
[TBL] [Abstract][Full Text] [Related]
4. Comparison of effectiveness and safety of ibandronate and minodronate combined with eldecalcitol in primary osteoporosis of women: A 1-year follow-up study.
Tanaka M; Nakamura Y; Itoh S; Kato Y
Osteoporos Sarcopenia; 2017 Mar; 3(1):37-44. PubMed ID: 30775501
[TBL] [Abstract][Full Text] [Related]
5. Effects of raloxifene on bone metabolism in postmenopausal women on chronic hemodialysis.
Nagatoya K; Nishimoto K; Shibahara N; Takahashi T; Kanehara H; Ueno N; Yasuda H; Okada S; Ueda H; Hirai K; Inoue T;
Clin Exp Nephrol; 2015 Oct; 19(5):939-46. PubMed ID: 25504368
[TBL] [Abstract][Full Text] [Related]
6. Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis.
Nakamura Y; Shimizu T; Asano T; Shimodan S; Ishizu H; Takahashi D; Takahata M; Iwasaki N
J Bone Miner Metab; 2021 Sep; 39(5):824-832. PubMed ID: 33821302
[TBL] [Abstract][Full Text] [Related]
7. Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.
Mori Y; Kasai H; Ose A; Serada M; Ishiguro M; Shiraki M; Tanigawara Y
Osteoporos Int; 2018 May; 29(5):1155-1163. PubMed ID: 29423715
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosis.
Ebina K; Noguchi T; Hirao M; Kaneshiro S; Tsukamoto Y; Yoshikawa H
J Bone Miner Metab; 2016 May; 34(3):243-50. PubMed ID: 26303222
[TBL] [Abstract][Full Text] [Related]
9. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
Tähtelä R; Seppänen J; Laitinen K; Katajamäki A; Risteli J; Välimäki MJ
Osteoporos Int; 2005 Sep; 16(9):1109-16. PubMed ID: 15605190
[TBL] [Abstract][Full Text] [Related]
10. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption.
Hannon RA; Clowes JA; Eagleton AC; Al Hadari A; Eastell R; Blumsohn A
Bone; 2004 Jan; 34(1):187-94. PubMed ID: 14751577
[TBL] [Abstract][Full Text] [Related]
11. Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
Nakatoh S
J Bone Miner Metab; 2018 Mar; 36(2):221-228. PubMed ID: 28293779
[TBL] [Abstract][Full Text] [Related]
12. Effects of monthly minodronate with or without eldecalcitol addition in osteoporosis patients with rheumatoid arthritis: An 18-month prospective study.
Suzuki T; Nakamura Y; Kato H
Osteoporos Sarcopenia; 2019 Dec; 5(4):122-127. PubMed ID: 31938731
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the activity of tartrate-resistant acid phosphatase isoform 5b in normal Chinese children--a novel marker for bone growth.
Chen CJ; Chao TY; Janckila AJ; Cheng SN; Ku CH; Chu DM
J Pediatr Endocrinol Metab; 2005 Jan; 18(1):55-62. PubMed ID: 15679069
[TBL] [Abstract][Full Text] [Related]
14. Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption.
Halleen JM
Anticancer Res; 2003; 23(2A):1027-9. PubMed ID: 12820342
[TBL] [Abstract][Full Text] [Related]
15. Effects of combined treatment with eldecalcitol and alendronate on bone mass, mechanical properties, and bone histomorphometry in ovariectomized rats: a comparison with alfacalcidol and alendronate.
Sugimoto M; Futaki N; Harada M; Kaku S
Bone; 2013 Jan; 52(1):181-8. PubMed ID: 23041510
[TBL] [Abstract][Full Text] [Related]
16. Additive effects of eldecalcitol in poorly responding long-term bisphosphonate treatment for osteoporosis.
Kamimura M; Ikegami S; Mukaiyama K; Koiwai H; Nakamura Y; Taguchi A; Kato H
Osteoporos Sarcopenia; 2019 Jun; 5(2):57-61. PubMed ID: 31346557
[TBL] [Abstract][Full Text] [Related]
17. Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption.
Halleen JM; Tiitinen SL; Ylipahkala H; Fagerlund KM; Väänänen HK
Clin Lab; 2006; 52(9-10):499-509. PubMed ID: 17078477
[TBL] [Abstract][Full Text] [Related]
18. Eldecalcitol improves mechanical strength of cortical bones by stimulating the periosteal bone formation in the senescence-accelerated SAM/P6 mice - a comparison with alfacalcidol.
Shiraishi A; Sakai S; Saito H; Takahashi F
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():119-23. PubMed ID: 24189542
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of combined treatment with raloxifene and alfacalcidol on bone density and biochemical markers of bone turnover in postmenopausal osteoporosis.
Majima T; Komatsu Y; Shimatsu A; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
Endocr J; 2008 Mar; 55(1):127-34. PubMed ID: 18219181
[TBL] [Abstract][Full Text] [Related]
20. Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment.
Nakamura Y; Suzuki T; Kato H
Ther Clin Risk Manag; 2017; 13():1343-1348. PubMed ID: 29062234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
